Nitric oxide (NO) has many features of an ideal pulmonary vasodilator. When inhaled, it has a rapid onset of action, is delivered directly to the lungs thereby minimising systemic side-effects, and improves ventilation-perfusion mismatch.\[1,2\] It was first approved by the Food and Drug Administration (FDA) in 1999 for use in neonates with persistent pulmonary hypertension of the newborn (PPHN). Since then, there has been considerable interest in its potential role as a pulmonary vasodilator in other conditions, and it is often employed in severe, refractory hypoxaemia secondary to acute respiratory distress syndrome (ARDS), and in pulmonary hypertension (PHT) following cardiac surgery.\[3\] It is an expensive treatment, and whether or not it improves outcomes remains controversial. Inhaled nitric oxide (iNO) has been shown to only transiently improve oxygenation,\[4-11\] and no improvement in survival has been demonstrated in patients with ARDS.\[1,4-6,10-12\] Most studies date back as far as 15 years and very few randomised controlled trials (RCTs) have been conducted in children.

Treatment with iNO has been shown to decrease mortality in patients with PHT following cardiac surgery.\[14,15\] Although some small studies have shown a decrease in the number of pulmonary hypertensive crises (PHTCs) postoperatively,\[15\] pooled data show otherwise.\[14,16\] There has also been no significant impact on mean pulmonary artery pressure (MPAP), mean arterial pressure (MAP), and oxygenation demonstrated.\[14,16\] The American Heart Association (AHA) and the European Consensus guidelines suggest early use of iNO for its possible effect in decreasing the number of PHTCs and decreasing pulmonary vascular resistance (PVR).\[11,17,18\] These guidelines were, however, developed in well-resourced settings. There are limited published data on the use of iNO in resource-limited settings, where extracorporeal membrane oxygenation (ECMO) is not available. It is also not known whether there are subgroups of patients with different underlying diseases or comorbidities that respond differently to treatment. In our unit, there are no protocols in place guiding its use, and the indications for use, dosage, weaning...
and discontinuation are usually left to the discretion of the attending physician.

Owing to the paucity of evidence showing improved outcomes with the use of iNO and the difference in context between our setting and that of most of the published data, we aimed to review its use and the outcomes of patients treated at a tertiary paediatric hospital in Western Cape Province, South Africa.

Methods
A retrospective, descriptive study was conducted reviewing all patients treated with iNO in the paediatric intensive care unit (PICU) at Red Cross War Memorial Children’s Hospital (RCWMCH) from 2011 - 2015. The 22-bed multi-disciplinary PICU admits ~1 300 patients annually, including acute medical admissions, trauma patients and post-surgery patients. Approximately 60% of admissions are acute medical admissions and ~320 children are admitted electively post-cardiac surgery each year.

Ethical approval was obtained from the RCWMCH Departmental Research Committee, as well as the Human Research Ethics Committee of the University of Cape Town (ref. no. 369/2016)

Patients who received treatment with iNO during the period being reviewed were identified using the electronic PICU database. All patients were included.

Data pertaining to response to treatment, duration of admission to PICU, underlying diagnoses, comorbidities and patient characteristics were extracted from the PICU electronic database and patients’ medical records. The duration of hospital admission and survival to discharge was obtained from the Clinicom database. Results of tests for retroviral disease, blood cultures and respiratory tract specimens were accessed via the National Health Laboratory System (NHLS). Echocardiographic evidence of pulmonary hypertension was obtained from the electronic database in the PICU as well as the department of cardiology’s electronic database of echocardiograms.

Data relating to costs of using the treatment were obtained from the pharmacy at RCWMH. Data were entered into a standardised data collection sheet and transferred into a Microsoft Excel spreadsheet. Names and folder numbers were removed to maintain confidentiality and anonymity. Missing data were included and marked as unknown. Medians, proportions and interquartile ranges (IQRs) were determined, and the Fisher’s exact test and Kruskall-Wallis rank tests were used to test the strength of associations. Stata software, version 12.0 (STATA Corp., USA) for Mac, was used to analyse data.

Results
Study Population
A total of 140 patients received treatment with iNO from 2011 - 2015 at RCWMCH. The characteristics of these patients are shown in Table 1.

The majority of the patients (83%; n=116/140) received treatment with iNO as rescue therapy, either during an acute PHTC following cardiac surgery or for refractory hypoxaemia thought to be related to raised pulmonary pressures in ARDS (Fig. 1). Less than a tenth of patients (5%; n=7/140) were treated prophylactically to prevent PHTC following cardiac surgery. The reason for initiation of treatment was not documented in 17 patients (Fig. 1).

All patients who were treated for ARDS had evidence of sepsis in the form of either a positive blood culture, sputum culture or viral panel on sputum. Of the children treated for ARDS, 8% (n=4/53) were admitted to the ICU for burns, 9% (n=5/53) following abdominal surgery, and 47% (n=25/53) had comorbid cardiac disease. Oral sildenafil was used to facilitate weaning off iNO in 47% (n=66/140) of patients in the cohort.

| Entire cohort (N=140 patients) |
|--------------------------------|
| Response to treatment in 64% (n=89/140) |
| Deaths in 31% (n=44/140) |

| PPHN patients (n=5) |
|---------------------|
| Response to treatment in 80% (n=4/5) |
| Deaths in 20% (n=1/5) |

| ARDS patients (n=53) |
|----------------------|
| Response to treatment in 64% (n=34/53) |
| Deaths in 53% (n=28/53) |

| Cardiac patients (n=82) |
|-------------------------|
| Response to treatment in 67% (n=55/82) |
| Deaths in 18% (n=15/82) |

| Adenoviral disease |
|--------------------|
| 19 patients |
| Response to treatment in 74% (n=14/19) |
| Deaths in 26% (n=5/19) |

| Tuberculosis |
|-------------|
| 4 patients |
| Response to treatment in 75% (n=3/4) |
| Deaths in 0% (n=0/4) |

Fig. 1. Characteristics of patients treated with iNO. (PPHN = pulmonary hypertension of the newborn; ARDS = acute respiratory distress syndrome; iNO = inhaled nitric oxide.)
Table 1. Patient characteristics

|                     | n (%) | p |
|---------------------|-------|---|
| Male                | 72 (51) |   |
| Female              | 68 (49) |   |
| Age (months), median (IQR) | 3 (1 – 9) |   |
| Weight (kg), median (IQR) | 4.5 (3.2 – 8.2) |   |
| Premature at birth¹ | 23 (16) |   |
| Underweight for age² | 72 (51) |   |
| Pulmonary tuberculosis | 4 (3) |   |
| Sepsis              | 101 (72) |   |
| HIV-positive        | 5 (4) |   |

IQR = interquartile range.
¹Unless otherwise specified.
²Gestational age <37 weeks at birth.
³Weight for age <–2 Z-score on WHO growth charts.

Table 2. Deaths in ICU and in hospital inpatients treated with iNO (N=140)

|                     | Deaths in ICU, n (%) | Deaths in hospital, n (%) |
|---------------------|----------------------|---------------------------|
| Entire cohort       | 36 (26)              | 44 (31)                   |
| PHT post cardiac surgery | 9 (11)              | 15 (18)                   |
| ARDS                | 26 (49)              | 28 (53)                   |
| PPHN                | 1 (20)               | 1 (20)                    |
| Rescue              | 29 (25)              | 34 (29)                   |
| Prophylaxis         | 0                    | 2 (25)                    |
| WFA <–2*            | 19 (26)              | 25 (35)                   |
| WFA >–2’            | 16 (25)              | 18 (29)                   |
| HIV-positive        | 3 (60)               | 3 (60)                    |
| HIV-negative        | 33 (25)              | 41 (31)                   |
| Premature at birth¹ | 8 (35)               | 9 (39)                    |
| Sepsis              | 24 (24)              | 31 (31)                   |
| TB                  | 0                    | 0                         |
| Adenovirus          | 11 (58)              | 12 (63)                   |
| Responders          | 22 (24)              | 26 (28)                   |
| Non-responders      | 5 (25)               | 6 (30)                    |

ICU = intensive care unit; iNO = inhaled nitric oxide; PHT = pulmonary hypertension; ARDS = acute respiratory distress syndrome; PPHN = pulmonary hypertension of the newborn; WFA = weight for age; TB = tuberculosis.

Table 3. Length of treatment and duration of admission of patients treated with iNO

|                     | Length of treatment, median (IQR) | ICU days, median (IQR) | Hospital days, median (IQR) |
|---------------------|-----------------------------------|------------------------|----------------------------|
| Cohort              | 3 (2 - 4)                         | 15 (9 - 23)            | 29 (19 - 50)               |
| PHT post-cardiac surgery | 3 (2 - 4)                         | 16 (9 - 22)            | 30 (20 - 51)               |
| ARDS                | 3 (2 - 4)                         | 13 (9 - 23)            | 28 (16 - 44)               |
| Adenovirus          | 3 (2 - 6)                         | 20 (11 - 26)           | 30 (21 - 52)               |
| Adenovirus: survivors | 4 (2 - 6)                         | 23 (20.5 - 28.5)       | 48 (29 - 60.5)             |
| Adenovirus: non-survivors | 3 (2 - 3)                        | 11.5 (7 - 25.5)        | 25.5 (12 - 47)             |
| PPHN                | 3.5 (2.3 - 4.8)                   | 23 (6 - 50.5)          | 38 (13 - 61)               |
| Underweight for age | 3 (2 - 4)                         | 16 (9 - 24.5)          | 33 (20 - 56.5)             |
| HIV                 | 5 (2.7 - 5)                       | 12 (4 - 17)            | 24 (13 - 33.5)             |
| Premature at birth¹ | 3 (2.3 - 3.75)                    | 18 (10 - 26)           | 34 (18 - 52)               |
| TB                  | 3.5 (2 - 9)                       | 23 (14.5 - 36.5)       | 38.5 (29 - 49.5)           |
| Sepsis              | 3 (2 - 5)                         | 18 (11 - 25)           | 32 (22 - 52)               |

iNO = inhaled nitric oxide; IQR = interquartile range; PHT = pulmonary hypertension; ARDS = acute respiratory distress syndrome; PPHN = pulmonary hypertension of the newborn; TB = tuberculosis.

The numbers of deaths in PICU compared with those at any point during hospital admission are shown in Table 2. Strengths of associations between patient characteristics and deaths in ICU and in hospital were tested, and patients with adenoviral disease had a significantly higher association with death in ICU (p=0.000) and death in hospital (p=0.000).

Patients with sepsis had longer lengths of treatment (p=0.02), longer lengths of ICU admission (p=0.00), and longer lengths of hospital admission (p=0.00) when associations between patient characteristics and length of treatment, and ICU and hospital days, were tested (Table 3).

Cost per annum
The total expenditure over 5 years was ZAR1 441 376 and the average annual expenditure was ZAR288 275 (Table 4).

Review of clinical practice
Reviewing of patient records revealed that practice was not standardised among clinicians, and objective parameters defining a response to treatment were not used. Attending clinician used their discretion to define treatment response and this was often based on an improvement in oxygen saturation alone. Oxygenation indices and echocardiographic findings of PHT were not used routinely. It was not possible to retrospectively calculate oxygenation indices in our cohort due to missing data.

Discussion
Our cohort comprised a young population with a median age of 3 months. A positive response to treatment was seen in 64% of our cohort and was similar in those treated for ARDS and PHT following cardiac surgery. This is similar to findings by Medjo et al.[8] and Day et al.[7] who reported positive responses in 69% and 58% of patients treated for ARDS, respectively. Fioretto et al.[9] reported a 94% response to treatment in patients with ARDS. This was however a small trial that probably pre-dated the change to lung protective ventilatory strategies. Our findings were limited as a standard definition of response to treatment was not used and a positive response was defined as any subjective improvement observed by the attending clinician.

We found that patients with adenoviral disease and tuberculosis demonstrated better responses to treatment than the rest of the cohort. Dobyns et al.[10] similarly reported that patients with more severe lung
disease, those with a high oxygenation index (OI) on starting treatment, and those that are immunocompromised respond better to treatment. This may be related to the role of iNO in modulating inflammation.\(^\text{[20]}\)

Inhaled NO is used universally in our unit as rescue therapy in patients with ARDS that are failing treatment with ventilation alone. There is however some evidence showing that early initiation of treatment, irrespective of disease severity improves outcomes.\(^\text{[19]}\)

The literature shows that iNO effects only a transient improvement in oxygenation.\(^\text{[20,15]}\) Part of the rationale behind continued use is that this temporary improvement in oxygenation may afford time for other therapies to be instituted or time for recovery of the underlying condition itself. Notwithstanding, a decrease in mortality following treatment with iNO has not been shown. Possible reasons are that these patients often have multi-organ dysfunction that is not improved by iNO, and because a response to treatment with improved oxygenation does not necessarily indicate an improvement in lung parenchymal disease.

The rationale for initiating iNO therapy in patients’ post-cardiac surgery is to decrease PVR in an attempt to ameliorate PHTCs. The lack of significant benefit with treatment, however, suggests that there are multiple factors contributing to the development of PHTCs, such as the ability of the right ventricle to handle an increase in PVR rather than the absolute increase in PVR itself.

Mortality in the entire cohort treated with iNO was 31%, and 53% in those with ARDS. This is higher than the reported mortality rate by Medjo et al.,\(^\text{[18]}\) Day et al.,\(^\text{[21]}\) Dobyns et al.\(^\text{[19]}\) and Dowell\(^\text{[13]}\) of 44%, 46%, 43% and 34%, respectively. Mortality was 63% in those with adenoviral disease, despite 71% of this group responding to treatment. We found no difference in mortality rate in responders v. non-responders. This is in line with the findings of Dowell\(^\text{[13]}\) and Lundin et al.\(^\text{[20]}\).

The cost of treating the cohort with iNO was ZAR1 441 376 during the period being reviewed, which is a considerable strain on a resource-limited setting. Gupta et al.\(^\text{[12]}\) was the first to show worse outcomes in terms of costs and morbidity in patients treated with iNO. We also report longer lengths of admission in patients with ARDS and those with TB. When the group with adenoviral infection is divided into those who survived to discharge and those who did not, we see markedly longer lengths of admission in the survivors, compounding the costs incurred in treating these patients, although these findings were not statistically significant. Patients with sepsis were associated with longer lengths of treatment \((p=0.02)\), longer lengths of ICU admission \((p=0.00)\), and longer lengths of hospital admission \((p=0.00)\).

**Study limitation**

The present study was a retrospective review without a control group, and many patient’s files and data points were missing. What we did find was that practice was not standardised in our unit owing to a lack of protocols guiding the indications for use, dosage, weaning and discontinuation of treatment. Echocardiography, which is the standard non-invasive investigation of choice in diagnosing PHT recommended by the AHA and European Consensus guidelines\(^\text{[13,17,18]}\) was not routinely used. The electronic cardiology database was accessed in an attempt to gather data on pulmonary pressures before and after treatment. This was abandoned because of missing data for most patients.

A positive response to treatment was judged by the attending clinician and was usually based on an increase in oxygen saturation alone. There was no defined increment in saturation that was used to denote a response. Oxygenation indices were not calculated in any of the patients that were treated, and it was not possible to calculate these retrospectively due to missing patient records and missing data points. Most studies defined a positive response as improvement in the oxygenation index \((OI)\) of 20E from baseline.\(^\text{[8,13,16,17,20]}\) Response to treatment as judged by an increase in oxygen saturation alone may have been confounded by adjunctive measures or therapies such as prone positioning, high frequency oscillatory ventilation, neuromuscular blockade or changes in ventilator settings. Response to treatment or lack thereof was not well documented in patients’ medical records. We often use iNO in our unit as rescue therapy in patients with PHTCs. However, iNO is used prophylactically in an attempt to prevent the onset of PHTCs in all the published literature.\(^\text{[8,13,16,20]}\) We did not have access to data regarding the number of PHTCs in our cohort. Sildenafil is recommended for use in all patients when weaning treatment with iNO.\(^\text{[18]}\) Only 47% of our cohort was treated concomitantly with sildenafil when weaning treatment with iNO.

**Conclusions**

We report that 64% of patients treated with iNO responded to treatment. Response to treatment was, however, poorly defined and not well documented in the medical records. Despite this response to treatment, mortality was high, particularly in those with ARDS and adenoviral infection. Length of hospital and PICU admission were also longer in these patients. Further studies in patients with ARDS stratified for underlying pathology are required. Moreover, we need further studies to look at long-term outcomes and cost effectiveness in resource-limited settings to justify the ongoing use of this expensive treatment.

In patients with PHT following cardiac surgery, iNO as rescue v. prophylactic therapy needs to be evaluated in good quality RCTs. It is also not clear whether the type of underlying cardiac condition is a predictor of response to iNO.

Overall, practice was not standardised in our unit and the cost of using this treatment is high.

The continued use of this treatment should be protocol driven, with clear criteria for indications for use, dosage and weaning, discontinuation, and determining a response to treatment. This should include the use of the OI and echocardiographic evidence of PHT.\(^\text{[13,17,18]}\)
1. Gebisporo E, Karam O, Wettersted J, Afdal H. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev 2018(6):CD002787. https://doi.org/10.1002/14651858.CD002787.pub3
2. Kimnoll JF, Ahmann SH. Inhaled nitric oxide therapy in children. Paediatric Respi Rev 2005;8(3):190-198. https://doi.org/10.1016/j.prrv.2005.06.02
3. Steinhein RH. Therapeutic approaches using nitric oxide in infants and children. Free Radical Bio Med 2011;51(5):1027-1034. https://doi.org/10.1016/j.freeradbiomed.2011.01.006
4. Adhikari NK, Dellinger RP, Lundin S, et al. Inhaled nitric oxide does not reduce mortality in patients with acute respiratory distress syndrome regardless of severity: Systematic review and meta-analysis. Crit Care Med 2014;42(2):404-412. https://doi.org/10.1097/ccm.0000000000001837
5. Afdal H, Boneski J, Möller AM, Wettersted J. Inhaled nitric oxide for acute respiratory distress syndrome and acute lung injury in adults and children: A systematic review with meta-analysis and trial sequential analysis. Anesth Analg 2011;112(6):1411-1421. https://doi.org/10.1213/ane.0b013e31820b8d85
6. Adhikari NK, Burnet KE, Friedrich JD, Granton JT, Cook DJ, Meade MO. Effect of nitric oxide on oxygenation and mortality in acute lung injury: Systematic review and meta-analysis. BMJ 2007;334(7597):779. https://doi.org/10.1136/bmj.39139.716794.55
7. Day BW, Allen EM, Wise MK. A randomised, controlled study of the 1-hour and 24-hour effects of inhaled nitric oxide therapy in children with acute hypoxaemic respiratory failure. Chest 1997;112(5):1324-1331. https://doi.org/10.1378/chest.112.5.1324
8. Dobyns EL, Cornfield DN, Anas NG, et al. Multicentre randomised controlled trial of the effects of inhaled nitric oxide therapy on gas exchange in children with acute hypoxaemic respiratory failure. J Pediatr 1999;134(4):406-412. https://doi.org/10.1016/S0022-3476(99)70196-4
9. Bonnici RA, Forstenberry J, Scheiber M, Cucchiar DA, Anas NG. Multicentre randomised controlled trial of inhaled nitric oxide for paediatric acute respiratory distress syndrome. J Pediatr 2015;166(2):365-369. https://doi.org/10.1016/j.jpeds.2014.10.011
10. Medjo R, Atamashkovic-Markovic M, Nikolic D, Cinarllo G, Djakic S. Inhaled nitric oxide therapy for acute respiratory distress syndrome in children. Indian Pediatr 2012;49(7):573-576.
11. Hansmann G, Anis C. Treatment of children with pulmonary hypertension. Expert consensus statement on the diagnosis and treatment of paediatric pulmonary hypertension. The European Paediatric Pulmonary Vascular Disease Network, endorsed by ISHLET and DGPK. Heart 2015;132(21):2037-2099. https://doi.org/10.1136/heartjnl-2015-309103
12. Gebistor F, Karam O, Wettersted J, Afdal H. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev 2018(6):CD002787. https://doi.org/10.1002/14651858.CD002787.pub3